Contact and place of performance
Mike Erickson
Los Alamos, NM 87545
USA
Los Alamos National Laboratory scientists have developed high-affinity human antibodies that can quickly detect and potentially treat deadly, antibiotic-resistant plague infections, helping protect against both natural outbreaks and bioterror threats. The Challenge: Plague, caused by the bacterium Yersinia pestis , remains a serious threat—not just as a rare but deadly natural infection, but also as a potential...
View moreThis innovation enables more accurate diagnosis and opens the door to new treatments for plague, even in the face of antibiotic resistance or biological warfare scenarios.
Key Advantages:
Market Applications:
Development Status: TRL 5
US Patent No. 11,702,465
LA-UR-25-28651
LANL Tech Partnerships: Unlock the Innovative Potential
Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.
LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact [email protected].
Note: This is not a call for external services for the development of this technology.
https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology
https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search
The Department of Energy, through Triad – DOE Contractor, is offering a technology licensing opportunity for PlagueGuard Antibodies developed at Los Alamos National Laboratory. These high-affinity human antibodies are designed to detect and potentially treat antibiotic-resistant infections caused by *Yersinia pestis*, the bacterium responsible for the plague. The innovation addresses challenges related to natural outbreaks and potential biothreats by providing extremely sensitive tools that target the F1 antigen of the bacterium. The technology is categorized under NAICS 325414 Biological Product (except Diagnostic) Manufacturing and PSC 6505 Drugs and Biologicals, with no set-aside (NONE/NONE) designated for the notice.
The antibodies exhibit picomolar binding affinities and can be utilized for both rapid diagnostics, such as lateral flow assays, and therapeutic applications, including radioimmunotherapy. These dual-application capabilities offer alternatives to traditional antibiotics, which is a critical advantage in combating engineered or naturally occurring antibiotic-resistant strains. The technology has reached a development status of TRL 5 and is protected under US Patent No. 11,702,465. Market applications for this innovation include public health, biodefense, pharmaceuticals, and veterinary biosafety.
Interested parties must respond by October 10, 2025. Performance is centered in Los Alamos, New Mexico, and the point of contact for this notice is Mike Erickson. The solicitation, identified as S-133813, includes two attachments: a .jpg file and a .png file both titled FCI-tech-summary-visual-PlagueGuard. The laboratory offers both exclusive and non-exclusive licensing agreements to move these inventions toward commercial innovation.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.